Arsenal Biosciences, Inc.

CEO Christopher Viehbacher has said consistently since he took the helm of Biogen in 2022 that the company will grow through both internal and external innovation, with an overarching goal of diversif

Biopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t

Venture capital investment in biopharmaceutical companies dropped by more than $1bn from the second to the third quarter, according to the latest data from Evaluate, but the amount of VC dollars inves

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia